HNN3.0

Project cooperationUpdated on 13 January 2026

In vivo CRISPR-mRNA Cas9 for KO in CD34 HSPCs

Co-founder and CEO at Lempo Therapeutics

Binyamina, Israel

About

Building on our foundational work in ex vivo CRISPR-edited bone marrow HSC therapies, we are initiating a transition toward in vivo hematopoietic genome editing. Our goal is to utilize the same high-efficiency gRNA from our clinical-track ex vivo program to target CD34+ HSCs in situ. This in vivo approach aims to circumvent the infrastructure requirements of specialized transplant centers and the physiological burden of myeloablative conditioning, thereby significantly lowering the barrier to treatment with an already preclinically proven therapy for patients with ANCA-associated glomerulonephritis and for cardiovascular diseases.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health

Type

  • Partner seeks Consortium/Coordinator

Organisation

Lempo Therapeutics

Start-up

Binyamina, Israel

Similar opportunities